中国妇幼健康研究2016，Vol.27Issue(4)：460-462,3.DOI:10.3969/j.issn.1673-5293.2016.04.015
卵巢癌患者血清肿瘤干细胞标志物CD133和miR-145的临床价值
Clinical significance of serum tumor stem cell marker CD133 and miR-145 in patients with ovarian cancer
摘要
Abstract
Objective To observe the expressions of serum CD133 and miR-145 in patients with ovarian cancer and their impact on prognosis.Methods From January 2010 to June 2014 totally 84 cases of ovarian cancer undergoing surgery in Medical College of Tongji University, Shanghai Eighth People's Hospital or Fushun Central Hospital were selected in ovarian cancer group.Thirty cases of benign tumor were selected in control group.The serum expressions of CD133 and miR-145 were detected by qRT-PCP method, and the relationship between them and age, tumor size, histological type, degree of differentiation, CA125 level as well as metastasis were analyzed.Results The serum CD133 expression level in ovarian cancer group was significantly higher than that in the control group (t=5.34, P<0.01) and significantly lowered after surgery compared with that before surgery (t=8.25, P<0.01).The expression level of miR-145 was significantly lower than that in the control group (t=5.06,P<0.01) and significantly increased after surgery than that before surgery (t=10.96, P<0.01).CD133 and miR-145 expressions in ovarian cancer patients were not significantly correlated with age, tumor size and histological type (t/F value ranged 0.03 -0.93, all P >0.05), but they were obviously correlated with tumor differentiation, CA125 level, lymph node metastasis and FIGO stage (t/F value ranged 2.01 -28.96, all P<0.05).Postoperative follow-up revealed that the 1-year recurrence rate was 76.79%in patients with high expression of CD133, which was significantly higher than 42.86%in patients with low expression (χ2 =8.06,P<0.05).In patients with high expression of miR-1451-year recurrence rate was 43.59%, which was significantly lower than 84.44%in those with low expression (χ2 =13.63,P<0.05).Conclusion The serum expression of CD133 is high but miR-145 is low in patients with ovarian cancer.They both involve in the development and progression of ovarian cancer, and combining detection of them is of great clinical significance in diagnosis and assessment of prognosis.关键词
卵巢癌/CD133/miR-145/诊断/预后Key words
ovarian cancer/CD133/miR-145/diagnosis/prognosis分类
医药卫生引用本文复制引用
王丹,王莉,王治洁..卵巢癌患者血清肿瘤干细胞标志物CD133和miR-145的临床价值[J].中国妇幼健康研究,2016,27(4):460-462,3.基金项目
上海市徐汇区卫生局医学科研课题青年资助项目(编号:SHXH201207) （编号:SHXH201207）
